385 related articles for article (PubMed ID: 23884751)
1. Neutrophil:lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung, and kidney cancer surgery.
Forget P; Machiels JP; Coulie PG; Berliere M; Poncelet AJ; Tombal B; Stainier A; Legrand C; Canon JL; Kremer Y; De Kock M
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S650-60. PubMed ID: 23884751
[TBL] [Abstract][Full Text] [Related]
2. Intraoperative use of ketorolac or diclofenac is associated with improved disease-free survival and overall survival in conservative breast cancer surgery.
Forget P; Bentin C; Machiels JP; Berliere M; Coulie PG; De Kock M
Br J Anaesth; 2014 Jul; 113 Suppl 1():i82-7. PubMed ID: 24464611
[TBL] [Abstract][Full Text] [Related]
3. The prognostic significance of lymphovascular invasion on biopsy specimens in lung cancer treated with definitive chemoradiotherapy.
Massabeau C; Filleron T; Wakil G; Rouquette I; Bachaud JM; Leguellec S; Delisle MB; Toulas C; Mazieres J; Cohen-Jonathan Moyal E
Clin Lung Cancer; 2012 Jan; 13(1):59-67. PubMed ID: 21856239
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor receptor 2 gene polymorphisms as predictors for tumor recurrence and overall survival in non-small-cell lung cancer.
Uzunoglu FG; Kaufmann C; Wikman H; Güngör C; Bohn BA; Nentwich MF; Reeh M; Pantel K; Bockhorn M; Kutup A; Mann O; Izbicki JR; Vashist YK
Ann Surg Oncol; 2012 Jul; 19(7):2159-68. PubMed ID: 22395975
[TBL] [Abstract][Full Text] [Related]
5. A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903).
Katakami N; Tada H; Mitsudomi T; Kudoh S; Senba H; Matsui K; Saka H; Kurata T; Nishimura Y; Fukuoka M
Cancer; 2012 Dec; 118(24):6126-35. PubMed ID: 22674529
[TBL] [Abstract][Full Text] [Related]
6. [Neutrophil-to-lymphocyte ratio predicts the survival in patients with post-operative recurrence of non-small cell lung cancer].
Wang X; Li K
Zhonghua Zhong Liu Za Zhi; 2014 Apr; 36(4):298-302. PubMed ID: 24989918
[TBL] [Abstract][Full Text] [Related]
7. Assessment of Prognostic Value of "Neutrophil to Lymphocyte Ratio" and "Prognostic Nutritional Index" as a Sytemic Inflammatory Marker in Non-small Cell Lung Cancer.
Kos FT; Hocazade C; Kos M; Uncu D; Karakas E; Dogan M; Uncu HG; Ozdemir N; Zengin N
Asian Pac J Cancer Prev; 2015; 16(9):3997-4002. PubMed ID: 25987075
[TBL] [Abstract][Full Text] [Related]
8. High pretreatment neutrophil-lymphocyte ratio predicts recurrence and poor prognosis for combined small cell lung cancer.
Shao N; Cai Q
Clin Transl Oncol; 2015 Oct; 17(10):772-8. PubMed ID: 26243392
[TBL] [Abstract][Full Text] [Related]
9. Forced expiratory volume in one second as a prognostic factor in advanced non-small cell lung cancer.
Lee JH; Song EM; Sim YS; Ryu YJ; Chang JH
J Thorac Oncol; 2011 Feb; 6(2):305-9. PubMed ID: 21150675
[TBL] [Abstract][Full Text] [Related]
10. Perioperative neutrophil:lymphocyte ratio and postoperative NSAID use as predictors of survival after lung cancer surgery: a retrospective study.
Choi JE; Villarreal J; Lasala J; Gottumukkala V; Mehran RJ; Rice D; Yu J; Feng L; Cata JP
Cancer Med; 2015 Jun; 4(6):825-33. PubMed ID: 25756351
[TBL] [Abstract][Full Text] [Related]
11. High neutrophil-to-lymphocyte ratio persistent during first-line chemotherapy predicts poor clinical outcome in patients with advanced urothelial cancer.
Rossi L; Santoni M; Crabb SJ; Scarpi E; Burattini L; Chau C; Bianchi E; Savini A; Burgio SL; Conti A; Conteduca V; Cascinu S; De Giorgi U
Ann Surg Oncol; 2015 Apr; 22(4):1377-84. PubMed ID: 25234022
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Significance of Preoperative Neutrophil-Lymphocyte Ratios in Patients with Stage I Non-small Cell Lung Cancer After Complete Resection.
Takahashi Y; Horio H; Hato T; Harada M; Matsutani N; Morita S; Kawamura M
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1324-31. PubMed ID: 26198075
[TBL] [Abstract][Full Text] [Related]
13. Are neutrophil/lymphocyte and platelet/lymphocyte rates in patients with non-small cell lung cancer associated with treatment response and prognosis?
Unal D; Eroglu C; Kurtul N; Oguz A; Tasdemir A
Asian Pac J Cancer Prev; 2013; 14(9):5237-42. PubMed ID: 24175807
[TBL] [Abstract][Full Text] [Related]
14. Neutrophil:lymphocyte ratio as a simple and novel biomarker for prediction of locoregional recurrence after chemoradiotherapy for squamous cell carcinoma of the anus.
Toh E; Wilson J; Sebag-Montefiore D; Botterill I
Colorectal Dis; 2014 Mar; 16(3):O90-7. PubMed ID: 24148256
[TBL] [Abstract][Full Text] [Related]
15. Preoperative Neutrophil-to-Lymphocyte Ratio is a Better Prognostic Serum Biomarker than Platelet-to-Lymphocyte Ratio in Patients Undergoing Resection for Nonmetastatic Colorectal Cancer.
Choi WJ; Cleghorn MC; Jiang H; Jackson TD; Okrainec A; Quereshy FA
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S603-13. PubMed ID: 25900206
[TBL] [Abstract][Full Text] [Related]
16. Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450).
De Ruysscher D; Wanders R; van Baardwijk A; Dingemans AM; Reymen B; Houben R; Bootsma G; Pitz C; van Eijsden L; Geraedts W; Baumert BG; Lambin P
J Thorac Oncol; 2012 Oct; 7(10):1547-55. PubMed ID: 22982655
[TBL] [Abstract][Full Text] [Related]
17. Esophageal carcinosarcoma: a unique entity with better prognosis.
Wang L; Lin Y; Long H; Liu H; Rao H; He Y; Rong T; Liang Y
Ann Surg Oncol; 2013 Mar; 20(3):997-1004. PubMed ID: 23010734
[TBL] [Abstract][Full Text] [Related]
18. Effect of hypertension on preoperative neutrophil-lymphocyte ratio evaluation of prognosis of renal cell carcinoma.
Sun J; Ning H; Sun J; Qu X
Urol Oncol; 2016 May; 34(5):239.e9-15. PubMed ID: 26803433
[TBL] [Abstract][Full Text] [Related]
19. Predictive Ability of Blood Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in Gastrointestinal Stromal Tumors.
Racz JM; Cleghorn MC; Jimenez MC; Atenafu EG; Jackson TD; Okrainec A; Venkat Raghavan L; Quereshy FA
Ann Surg Oncol; 2015 Jul; 22(7):2343-50. PubMed ID: 25472648
[TBL] [Abstract][Full Text] [Related]
20. Dose-escalation study of three-dimensional conformal thoracic radiotherapy with concurrent S-1 and cisplatin for inoperable stage III non-small-cell lung cancer.
Harada H; Nishio M; Murakami H; Ohyanagi F; Kozuka T; Ishikura S; Naito T; Kaira K; Takahashi T; Horiike A; Nishimura T; Yamamoto N
Clin Lung Cancer; 2013 Jul; 14(4):440-5. PubMed ID: 23540866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
